Fortrea Holdings Inc. (FTRE) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Fortrea Holdings Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: Fortrea is a leading global contract research organization (CRO) providing biopharmaceutical product and medical device development solutions. The company operates in a single reporting segment, Clinical Services, offering phase I through IV clinical trial management, clinical pharmacology, and consulting services. Fortrea was spun off from Labcorp Holdings Inc. in June 2023. In 2024, the company sold its Enabling Services Segment (Patient Access and Endpoint Clinical), which is now reported as discontinued operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenues | $2,723.4 million | $2,696.4 million | +1.0% |
| Operating Loss | $(872.6) million | $(161.9) million | Worsened |
| Net Loss | $(986.2) million | $(328.5) million | Worsened |
| Diluted EPS (Continuing Ops) | $(10.81) | $(3.03) | Worsened |
| Goodwill Impairment | $797.9 million | $0 | N/A |
| Backlog | $7.7 billion | N/A | N/A |
| Cash and Cash Equivalents | $174.6 million | $118.5 million | +47.3% |
| Total Debt (Principal) | $1,066.3 million | $1,640.0 million (approx) | Reduced |
| Operating Cash Flow | $113.5 million | $262.8 million | -56.8% |
Note: The 2025 Net Loss includes a non-cash goodwill impairment charge of $797.9 million. Excluding this charge, the company generated positive operating income from its Clinical Services segment ($87.4 million).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 1.0% to $2.72 billion, driven by a 0.8% organic growth rate. Growth was led by the clinical pharmacology business, partially offset by lower clinical development revenues due to a mix of complex, longer-duration studies and lower functional service provider revenue.
- Goodwill Impairment: The company recorded a significant non-cash goodwill impairment of $797.9 million in the Clinical Development reporting unit. This was triggered by sustained declines in the company's share price and macroeconomic uncertainties. Interim tests in Q1 and Q2 2025 resulted in impairments of $488.8 million and $309.1 million, respectively.
- Cost Structure: Direct costs increased 2.7% to $2.22 billion (81.5% of revenue), driven by higher pass-through costs and stock compensation. Selling, General, and Administrative (SG&A) expenses decreased 18.6% to $456.4 million, primarily due to lower transition service agreement costs and IT costs following the expiration of the Labcorp Transition Services Agreement.
- Debt Reduction: The company reduced its debt load significantly. It repurchased $75.7 million of its 7.50% Senior Notes in Q4 2025 and had previously paid down term loans in 2024. As of year-end, $447.7 million remained available on its revolving credit facility.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Fortrea continues to focus on its three strategic pillars: commercial, operational, and financial excellence. The company is investing in AI and machine learning to drive speed and efficiency in clinical trials. Management expects to drive operating leverage as revenue grows. The company maintains a disciplined approach to pricing and resource management to support margin expansion.
Key Risks and Contingencies:
- Customer Concentration: One customer accounted for 18.1% of 2025 revenue. The top 20 customers represented 69% of total revenue.
- Backlog Volatility: While backlog stands at $7.7 billion, management notes that backlog is not a consistent indicator of future revenue due to potential cancellations, delays, or scope reductions by customers.
- Legal Proceedings: A shareholder class action lawsuit (Lucas Deslande v. Fortrea Holdings Inc.) was filed in June 2025 alleging securities law violations. The company intends to defend vigorously but notes the outcome is uncertain.
- Regulatory & Compliance: The company faces risks related to global data privacy laws (GDPR, CCPA), anti-corruption laws (FCPA), and evolving regulations regarding AI in clinical research.
- Spin-Off Liabilities: Fortrea remains subject to contingent liabilities from its separation from Labcorp, including potential indemnification obligations.
Investor Verification Checklist
- Goodwill Impairment Sustainability: Verify if the $797.9 million impairment is a one-time event or if further impairments are likely given the share price volatility and macroeconomic conditions.
- Organic Growth Drivers: Assess the sustainability of the 0.8% organic revenue growth, specifically the reliance on clinical pharmacology versus the headwinds in clinical development.
- Debt Covenant Compliance: Confirm continued compliance with financial covenants (net leverage and interest coverage ratios) under the Credit Agreement, especially given the recent covenant amendments.
- Customer Concentration Risk: Monitor the stability of the top customer relationships, particularly the single customer representing 18.1% of revenue.
- Legal Exposure: Track the progress of the shareholder class action lawsuit and any potential settlement costs or reputational impact.
- Cash Flow Conversion: Analyze the decline in operating cash flow ($113.5M vs $262.8M in 2024) and its drivers, specifically the impact of the receivables securitization program and working capital changes.